Andreev K, Jones JC, Seiler P, Kandeil A, Turner J. Antiviral Susceptibility of Highly Pathogenic Avian Influenza A(H5N1) Viruses Circulating Globally in 2022-2023. J Infect Dis. 2023 Sep 28:jiad418
The antiviral susceptibility of currently circulating (2022-2023) highly pathogenic avian influenza (HPAI) A(H5N1) viruses was assessed by genotypic and phenotypic approaches. The frequency of neuraminidase (NA) and polymerase acidic (PA) substitutions associated with reduced inhibition by NA inhibitors (NAIs) (21/2698, 0.78%) or by the PA inhibitor baloxavir (14/2600, 0.54%) was low. Phenotypic testing of 22 clade 2.3.2.1a and 2.3.4.4b viruses revealed broad susceptibility to NAIs and baloxavir concluding that most contemporary HPAI A(H5N1) viruses retain susceptibility to antiviral drugs. Novel NA-K432E and NA-T438I substitutions (N2 numbering) were identified at elevated frequencies (104/2698, 3.85%) and caused reduced zanamivir and peramivir inhibition.
See Also:
Latest articles in those days:
- Molecular characterisation of influenza B virus from the 2017/18 season in primary models of the human lung reveals improved adaptation to the lower respiratory tract 8 hours ago
- Survivability of H5N1 Avian Influenza Virus in Homemade Yogurt, Cheese and Whey 8 hours ago
- Out of the blue: Detection of a unique highly pathogenic avian influenza virus of subtype H7N5 in Germany 8 hours ago
- Genetic Characterization and Receptor Binding analysis of a Novel H5N1 HPAI Virus with a H6Nx-Derived PA Gene in Guangdong, China 8 hours ago
- Avian influenza overview June–September 2024 19 hours ago
[Go Top] [Close Window]